Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Devonian Health Group ( (TSE:GSD) ) has shared an announcement.
Devonian Health Group Inc. will implement a one-for-sixty reverse stock split of its common shares as it prepares for a potential additional listing on a U.S. stock exchange, following shareholder approval and pending final acceptance from the TSX Venture Exchange. The consolidation, expected to take effect around January 22, 2026, will reduce the number of outstanding shares from about 165.9 million to roughly 2.8 million, with the aim of increasing the share price to broaden the investor base and meet minimum price requirements for U.S. and other exchange listings, while maintaining the company’s existing trading symbols and ensuring a smooth transition for both registered and beneficial shareholders.
More about Devonian Health Group
Devonian Health Group Inc. is a clinical-stage pharmaceutical company focused on developing drugs for autoimmune fibroinflammatory diseases, targeting unmet medical needs in indications such as atopic dermatitis, radiodermatitis and ulcerative colitis. The company also develops high-value cosmeceutical products using its proprietary approach and operates Altius Healthcare LP, a commercialization subsidiary that markets licensed prescription pharmaceutical products in Canada. Founded in 2015, Devonian positions itself at the intersection of specialty pharmaceuticals and cosmeceuticals.
Average Trading Volume: 31,005
Technical Sentiment Signal: Buy
Current Market Cap: C$29.87M
For detailed information about GSD stock, go to TipRanks’ Stock Analysis page.